DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,871 filers reported holding DANAHER CORPORATION in Q3 2021. The put-call ratio across all filers is 1.50 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $36,812,394 | +4.4% | 148,377 | +1.0% | 1.43% | +8.8% |
| Q2 2023 | $35,263,738 | -3.1% | 146,932 | +1.8% | 1.32% | -4.6% |
| Q1 2023 | $36,386,584 | -4.5% | 144,368 | +0.6% | 1.38% | -9.0% |
| Q4 2022 | $38,107,524 | +0.7% | 143,574 | -2.0% | 1.52% | -4.7% |
| Q3 2022 | $37,832,000 | +1.0% | 146,469 | -0.8% | 1.59% | +5.4% |
| Q2 2022 | $37,447,000 | -14.2% | 147,708 | -0.8% | 1.51% | -6.7% |
| Q1 2022 | $43,659,000 | -10.6% | 148,840 | +0.3% | 1.62% | -6.4% |
| Q4 2021 | $48,824,000 | +7.5% | 148,397 | -0.5% | 1.73% | -2.0% |
| Q3 2021 | $45,412,000 | +5.5% | 149,166 | -7.0% | 1.76% | +6.1% |
| Q2 2021 | $43,063,000 | +17.2% | 160,466 | -1.7% | 1.66% | +9.6% |
| Q1 2021 | $36,729,000 | +0.2% | 163,180 | -1.1% | 1.52% | -4.9% |
| Q4 2020 | $36,668,000 | +0.1% | 165,069 | -3.0% | 1.60% | -14.0% |
| Q3 2020 | $36,645,000 | +8.2% | 170,180 | -11.2% | 1.86% | +1.3% |
| Q2 2020 | $33,872,000 | +22.9% | 191,549 | -3.8% | 1.83% | +8.5% |
| Q1 2020 | $27,555,000 | -12.3% | 199,082 | -2.7% | 1.69% | +5.7% |
| Q4 2019 | $31,403,000 | +5.5% | 204,607 | -0.7% | 1.60% | -0.9% |
| Q3 2019 | $29,768,000 | -0.5% | 206,105 | -1.6% | 1.61% | -2.2% |
| Q2 2019 | $29,930,000 | -3.1% | 209,419 | -10.5% | 1.65% | -5.1% |
| Q1 2019 | $30,879,000 | +21.7% | 233,898 | -4.9% | 1.74% | +13.8% |
| Q4 2018 | $25,371,000 | -4.3% | 246,034 | +0.9% | 1.53% | +3.5% |
| Q3 2018 | $26,508,000 | +12.0% | 243,950 | +1.7% | 1.48% | +3.8% |
| Q2 2018 | $23,667,000 | +460.6% | 239,831 | +198.9% | 1.42% | +452.9% |
| Q1 2018 | $4,222,000 | -81.1% | 80,226 | -66.6% | 0.26% | -81.0% |
| Q4 2017 | $22,288,000 | +130.8% | 240,120 | +113.3% | 1.35% | +119.3% |
| Q3 2017 | $9,656,000 | +3.6% | 112,567 | +1.9% | 0.62% | -0.6% |
| Q2 2017 | $9,320,000 | +1.1% | 110,438 | +2.5% | 0.62% | -2.1% |
| Q1 2017 | $9,218,000 | +14.1% | 107,774 | +3.9% | 0.63% | +6.9% |
| Q4 2016 | $8,078,000 | +1.3% | 103,775 | +2.0% | 0.59% | -3.7% |
| Q3 2016 | $7,976,000 | -17.7% | 101,745 | +6.0% | 0.62% | -22.8% |
| Q2 2016 | $9,691,000 | +9.7% | 95,954 | +0.9% | 0.80% | -5.7% |
| Q1 2016 | $8,831,000 | 0.0% | 95,077 | 0.0% | 0.85% | 0.0% |
| Q4 2015 | $8,831,000 | +9.6% | 95,077 | +0.5% | 0.85% | -5.5% |
| Q3 2015 | $8,060,000 | +1.5% | 94,595 | +2.0% | 0.90% | +70.5% |
| Q2 2015 | $7,937,000 | – | 92,727 | – | 0.52% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |